(Disclaimer/shameless advertisement: I am a co-founder of a project in the problem domain. We are currently in seed stage, fundraising mode, and are going to ha

(Disclaimer/shameless advertisement: I am a co-founder of a project in the problem domain. We are currently in seed stage, fundraising mode, and are going to have a look at the U.S. east/west coast soon). I am quite happy to see YC to jump on the SynBio train. While other specialized accelerators such as IndieBio [1] have been first in this fairly unclaimed industry sector, I expect their involvement to trigger a cascade in professional investment that will help the bulk of us to get more money. In contrary to software (and for a multitude of reasons), biotech investments have recovered at a much slower pace since the 2008 crash. If I get around to make a solid write up, I would like to compare the wet/hardware biotech startup accelerator experience. As in software, biotech tools have made a great improvement and became cheaper by orders of magnitude. However, the development workflow is still different, and many things such a reproducibility, lab environment, specialized talent are not as easy to come by in a lean and fast accelerator program. 3 month to MVP is a true challenge - we were quite lucky that we made it [2]. Biotech can be far more complicated as software on the business side of things, and going lean is often not really an option (think production standards, ISO/cGMP). A 1:1 copy of the software accelerator model is definitely not enough. [1] http://indie.bio http://indie.bio [2] http://sothicbio.science http://sothicbio.science